RETROSPECTIVE COHORT ANALYSIS OF THE PATTERNS AND PREDICTORS OF METFORMIN TREATMENT CHANGE IN A MEDICARE ADVANTAGE PATIENT POPULATION FROM A LARGE NATIONAL HEALTH PLAN
Author(s)
Hazel-Fernandez L1, Xu Y2, Moretz C1, Meah Y3, Baltz J3, Lian J4, Bouchard JR5
1Comprehensive Health Insights, Humana, Miramar, FL, USA, 2Humana, Inc., Louisville, KY, USA, 3Humana Inc., Louisville, KY, USA, 4Novo Nordisk Inc., Princeton, NJ, USA, 5Novo Nordisk Inc., Plainsboro, NJ, USA
OBJECTIVES: No consensus exists among the ADA and the AACE guidelines regarding therapy intensification for patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin (MET) monotherapy. This study aimed to understand the treatment regimens of Medicare Advantage with Prescription Drug coverage (MAPD) patients in a large national health plan who newly initiate MET monotherapy, and assess factors associated with changes in therapy in the 12 months after MET initiation. METHODS: This was a retrospective cohort analysis of medical and pharmacy claims of 17,527 MAPD members aged 18-89, with ≥1 medical claim containing a primary diagnosis or ≥2 medical claims containing a secondary diagnosis of T2DM, and with an initial prescription fill for MET between 1/1/2008 and 9/30/2011. Demographic and clinical characteristics were analyzed using descriptive statistics; factors associated with treatment changes were examined using Cox proportional hazard regression models. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PDB120
Topic
Epidemiology & Public Health, Health Service Delivery & Process of Care
Topic Subcategory
Disease Classification & Coding, Prescribing Behavior, Treatment Patterns and Guidelines
Disease
Diabetes/Endocrine/Metabolic Disorders